LUCID CAPITAL MARKETS Initiates Coverage On Microbot Medical with Buy Rating, Announces Price Target of $4

Benzinga Newsdesk www.benzinga.com Neutral 66.2%

Neg 0% Neu 66.2% Pos 0%

LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Microbot Medical (NASDAQ:MBOT) with a Buy rating and announces Price Target of $4.